News

Latest news

Hide mandatory notifications of trade

Mandatory notification of trades - Lars Høie

(Oslo, Norway, 9 September 2016) Mandatory Notification of trades

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES

Reference is made to the stock exchange notice dated 18 August 2016 regarding a private placement of 525,000,000 new shares at subscription price of NOK 0.10 per share ("Private Placement") in Bionor Pharma ASA ("Bionor", ticker "BIONOR"), and the extraordinary general meeting ("EGM") of Bionor held today in which the Private Placement was resolved by Bionor.

At the EGM certain investors have subscribed for and been allocated new shares in Bionor, as separately notified to the market in a separate stock exchange notice dated today, 18 August 2016.

Lars Høie currently holds 75,253,370 shares in the Company and 15,253,370 warrants. On the basis of the currently registered share capital of the Company (prior to the registration of the Private Placement) his total holding of shares and warrants equals 26.9%.Following registration of the share capital increase with respect to the shares issued in the Private Placement, Lars Høie will hold 8.8% of the issued shares of the Company. His total holding of shares and warrants calculated on the basis of the share capital following the registration of the Private Placement equals 10.5%.

This information is subject to the disclosure requirements set out in section 4-3 of the Norwegian Securities Trading Act.

Further information
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com

Link to announcement in pdf